Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease.
Sfikakis
P P
PP
Kaklamanis
P H
PH
Elezoglou
A
A
Katsilambros
N
N
Theodossiadis
P G
PG
Papaefthimiou
S
S
Markomichelakis
N
N
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D031300:Retinal Vasculitis / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab